PMID- 35921253
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221003
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 52
IP  - 10
DP  - 2022 Oct
TI  - Real-world outcomes of molecular targeted agents for patients with hepatocellular 
      carcinoma over 80 years old.
PG  - 859-871
LID - 10.1111/hepr.13818 [doi]
AB  - AIM: There is insufficient evidence regarding the safety and efficacy of 
      molecular targeted agents (MTAs) for elderly patients with hepatocellular 
      carcinoma (HCC), who are likely to be vulnerable to adverse events (AEs) of 
      therapy. The aim of this study was to compare sorafenib and lenvatinib use in 
      elderly patients with HCC from the viewpoint of overall survival (OS) and rate of 
      AE-induced MTA discontinuation. METHODS: This retrospective study included 
      patients with HCC over 80 years old who received first-line molecular targeted 
      therapy (MTT) at four hospitals between June 2009 and September 2019. They were 
      divided into three groups according to the era and type of first-line MTA: 
      E1-Sora (sorafenib, between 2009 and 2016), E2-Sora (sorafenib, between 2017 and 
      2019), and E2-Len (lenvatinib, between 2017 and 2019). RESULTS: The study 
      included 173 patients (E1-Sora, n = 79; E2-Sora, n = 50; E2-Len, n = 44) with a 
      median age of 81.9 years (range, 80-93 years). Median OS was 15.1 months in the 
      entire cohort (E1-Sora, 12.7 months; E2-Sora, 20.5 months; E2-Len, 10.3 months). 
      The rate of treatment discontinuation due to AEs was high in the entire cohort, 
      especially in E1-Sora and E2-Len (49.4% in E1-Sora, 28.0% in E2-Sora, and 54.6% 
      in E2-Len, p = 0.0753). More E2-Sora patients received subsequent MTT than E2-Len 
      patients (E2-Sora, 50%; E2-Len, 28.6%; p = 0.0111). CONCLUSION: Both sorafenib 
      and lenvatinib were effective and feasible for elderly patients with HCC. In 
      terms of discontinuation due to AEs and subsequent MTT, sorafenib might be more 
      desirable for elderly patients with HCC over 80 years.
CI  - (c) 2022 Japan Society of Hepatology.
FAU - Sato, Rui
AU  - Sato R
AD  - Division of Interventional Radiology, Shizuoka Cancer Center, Sunto-Gun, Japan.
FAU - Moriguchi, Michihisa
AU  - Moriguchi M
AD  - Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, 
      Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Iwai, Kenji
AU  - Iwai K
AD  - Division of Interventional Radiology, Shizuoka Cancer Center, Sunto-Gun, Japan.
FAU - Tsuchiya, Satoshi
AU  - Tsuchiya S
AD  - Division of Interventional Radiology, Shizuoka Cancer Center, Sunto-Gun, Japan.
FAU - Seko, Yuya
AU  - Seko Y
AD  - Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, 
      Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Takahashi, Aya
AU  - Takahashi A
AD  - Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, 
      Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Kobayashi, Kazufumi
AU  - Kobayashi K
AD  - Department of Gastroenterology, Graduate School of Medicine, Chiva University, 
      Chiba, Japan.
FAU - Ogasawara, Sadahisa
AU  - Ogasawara S
AUID- ORCID: 0000-0002-6540-9064
AD  - Department of Gastroenterology, Graduate School of Medicine, Chiva University, 
      Chiba, Japan.
FAU - Watanabe, Shunji
AU  - Watanabe S
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Tochigi, Japan.
FAU - Morimoto, Naoki
AU  - Morimoto N
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Tochigi, Japan.
FAU - Kato, Naoya
AU  - Kato N
AD  - Department of Gastroenterology, Graduate School of Medicine, Chiva University, 
      Chiba, Japan.
FAU - Itoh, Yoshito
AU  - Itoh Y
AD  - Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, 
      Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Aramaki, Takeshi
AU  - Aramaki T
AD  - Division of Interventional Radiology, Shizuoka Cancer Center, Sunto-Gun, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220817
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - discontinuation due to adverse events
OT  - elderly patients with HCC
OT  - lenvatinib
OT  - molecular targeted agent
OT  - sorafenib
EDAT- 2022/08/04 06:00
MHDA- 2022/08/04 06:01
CRDT- 2022/08/03 13:22
PHST- 2022/06/19 00:00 [revised]
PHST- 2022/02/09 00:00 [received]
PHST- 2022/07/15 00:00 [accepted]
PHST- 2022/08/04 06:00 [pubmed]
PHST- 2022/08/04 06:01 [medline]
PHST- 2022/08/03 13:22 [entrez]
AID - 10.1111/hepr.13818 [doi]
PST - ppublish
SO  - Hepatol Res. 2022 Oct;52(10):859-871. doi: 10.1111/hepr.13818. Epub 2022 Aug 17.